Dupixent has been authorized in the EU as the first and sole treatment for young children suffering from eosinophilic esophagitis.

Hanmi Introduces New Obesity Treatment ‘HM17321’: A Breakthrough in Addressing Muscle Loss Linked to GLP-1.

Minghui Pharmaceutical Reports Positive Early Findings from Phase I Trial of MHB039A, a New Bispecific Antibody Targeting PD-1 and VEGF.

Arcus Biosciences reports that the combination of Domvanalimab and Zimberelimab enhanced overall survival in the ARC-10 trial involving patients with high PD-L1 NSCLC.

OSE Immunotherapeutics reports noteworthy and statistically significant findings from the Phase 2 trial of Lusvertikimab, an anti-IL7R monoclonal antibody.

European Medicines Agency Approves Marketing Authorization Application for AVT05, a Biosimilar to Simponi® (golimumab).

Korro Bio has announced that it has submitted an application to the Bellberry HREC for a Phase 1/2 clinical trial of KRRO-110 targeting AATD.

HuidaGene Therapeutics Secures FDA Approval for HG202, the First CRISPR/Cas13 RNA-Editing Treatment for Macular Degeneration.

Cytoki Pharma has dosed the first patient in its Phase 2 trial for CK-0045, targeting obesity and Type 2 diabetes.

Viking Therapeutics has announced that new clinical findings from its VK2735 obesity initiative were featured in two poster sessions at ObesityWeek® 2024.

Ionis has revealed that the FDA has accepted the New Drug Application for donidalorsen, intended for the preventive treatment of HAE.

CinFina Pharma showcases encouraging Phase 1 study findings during a poster session for CIN-109 and a late-breaking poster for CIN-110.